Tonix Pharma To Test Its Fibromyalgia Candidate In Long COVID Syndrome
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) plans to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for Long COVID Syndrome (Long COVID), which…
Theravance Biopharma Stock Drops After Nezulcitinib Disappoints In COVID-19 Study
Theravance Biopharma Inc (NASDAQ:TBPH) has announced top-line results from its Phase 2 study evaluating nezulcitinib for hospitalized patients with confirmed COVID-19…
Tarsus Pharmaceuticals’ TP-03 Hits Primary, Secondary Endpoints In Demodex Blepharitis Study
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) has reported topline data from Phase 2b/3 Saturn-1 trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) in patients…
Immutep To Initiate Efti Triple Combination Therapy Trial In Solid Tumors, Launches $60M Placement
Immutep (NASDAQ:IMMP) will begin a Phase 1 trial to evaluate its lead product candidate, eftilagimod alpha (efti or IMP321), in conjunction…
Novartis Touts More Positive Zolgensma Data In Spinal Muscular Atrophy Patients
Novartis AG (NYSE:NVS) announced new data from the completed two-copy cohort of Phase 3 SPR1NT trial of Zolgensma (onasemnogene abeparvovec), gene…
MediciNov’s MN-166 Reduces Odds Of Heavy Drinking by 45% After 14 Days Of Treatment
MediciNov Inc (NASDAQ:MNOV) has announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use…
Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis; Co. Reports ‘Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints’
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,
Pfizer COVID-19 Vaccine Approved For 12-15 Age Group In New Zealand
The Pfizer Inc (NYSE: PFE)/BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine has received provisional approval for use in the age group 12 to 15 from New Zealand's medical regulator, Stuff
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.
Europe Approves Sanofi’s Expanded Use Of Aubagio In Pediatric Patients With Multiple Sclerosis
The European Commission has approved Sanofi SA’s (NASDAQ:SNY) Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of…